The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
about
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerPI3K/Akt/mTOR inhibitors in breast cancerTreatment Individualization in Colorectal CancerDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersMolecular phenotypes of colorectal cancer and potential clinical applicationsSplicing Regulators and Their Roles in Cancer Biology and TherapyWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayPathways and therapeutic targets in melanomaTargeted therapies in development for non-small cell lung cancerEffects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeLong-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Maximising the potential of AKT inhibitors as anti-cancer treatmentsCombination treatment including targeted therapy for advanced hepatocellular carcinomaTargeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?RSK3: A regulator of pathological cardiac remodelingCytoprotection "gone astray": Nrf2 and its role in cancerSelective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKPI3K and cancer: lessons, challenges and opportunitiesActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancerZeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentAntitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo.The MAPK pathway as an apoptosis enhancer in melanoma.Oncogenic KRAS signalling in pancreatic cancer.Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.Development of siRNA payloads to target KRAS-mutant cancer.Novel somatic mutations to PI3K pathway genes in metastatic melanomaDevelopment of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.
P2860
Q26744721-14B82CC6-0CE8-4E67-8F30-3BA66021DC1CQ26771394-F51FB39B-A506-4BF9-8CC3-E9DC5FF2F1F9Q26776215-4C59DFFC-5718-4114-860F-1803A8D4A16BQ26781362-7E80326C-D210-4CB1-9B6C-0C1281EDB0FAQ26785725-5C90D61D-1FDB-4359-90B7-02B7AAE634DBQ26798158-5943979C-5428-4960-8210-E4C01EFACBDBQ26825780-2D08B977-CED5-468E-988C-F9B8DA94D2F1Q26865736-9B74CD00-7E73-422F-8553-D4E117D0B54EQ27022852-B2ADE2C0-1BAB-41ED-A391-86649282CB6AQ27852994-5AB7E2AA-1646-404A-A3AC-16096DE8E4D6Q27853295-5AD16061-7832-4FE9-B817-93865DFC9E98Q27853310-F9545D1D-BD8D-4516-9BA9-816C9DE43A11Q28072254-AED70D2D-EE17-4090-A038-60CBCB4ECD01Q28077738-F9451C71-4FA5-40FA-9C27-EA826D9772BDQ28079596-B8773A0A-6B37-4A8D-8E9A-4DC13EE0926FQ28086916-7204FAF9-D8FC-4105-BB78-12106895D5D4Q28393784-3821C6DD-F302-463B-A3CB-3DC86D06AA8DQ28547522-F635780A-BCB1-4938-B2A1-62731FF749BBQ28833740-3E704C6E-9F63-4C70-A9AA-C99A8094429EQ30080017-7166F810-F621-4540-8453-6F21DBAF0AA6Q30252408-CC8CD374-A4B4-469A-95A5-E629F2F10355Q33408049-625C1B26-E713-4E89-B4CF-EE3FB5B8DE86Q33439312-C3BE65CB-F6FC-4218-80A5-7EE8241A33E8Q33571352-23A22BA1-5528-4217-A3DA-6BAB8B04404CQ33591361-D907BA39-C3A2-4F3F-9A1F-76FA71095FE5Q33591690-019CA2EF-E3CB-4123-9D0C-1D07F729D099Q33687272-E429848A-46CB-472F-9AFA-816F1E2DF9D8Q33776641-BB54D026-229E-4DEC-B3E6-A0E7160A4487Q33820374-7AF89E5B-C9AF-4587-A272-FD3AFE4BB256Q33825288-28C499FE-73C8-47C7-8CDF-8F540FD18ACBQ34075366-AA54E613-A526-431D-8CBA-F83657CD09E6Q34104135-0EE48DE9-982B-404D-AC35-AF4D112CB984Q34113460-01EC11F5-C0F7-4B76-8640-C6FFA97F210FQ34153696-63AC8D59-21BC-4C31-9C28-BCCF24387BA2Q34203585-9F2F992E-93D7-454B-BFED-A39EEA051A65Q34223118-D4AD1681-9EDB-4897-9F45-04F1812AC9B1Q34287993-E55A7B9C-91AA-42CE-A585-3829BE16BBB4Q34389570-3A6E105D-4E3F-48FC-9E2D-FB5815B26C82Q34525925-EEF4C278-BABB-4642-934D-DA703BAA49DEQ34599550-7891CDC7-9C0D-41FF-96A1-DC795309F948
P2860
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The clinical effect of the dua ...... patients with advanced cancer.
@en
The clinical effect of the dua ...... patients with advanced cancer.
@nl
type
label
The clinical effect of the dua ...... patients with advanced cancer.
@en
The clinical effect of the dua ...... patients with advanced cancer.
@nl
prefLabel
The clinical effect of the dua ...... patients with advanced cancer.
@en
The clinical effect of the dua ...... patients with advanced cancer.
@nl
P2093
P1476
The clinical effect of the dua ...... patients with advanced cancer.
@en
P2093
Amita Patnaik
Anthony W Tolcher
Aracely Cavazos
Brianne Kaiser
Cathy Alvarez
Drew W Rasco
Gina L Mangold
Kyriakos P Papadopoulos
Leslie Smetzer
Lon S Smith
P304
P356
10.1158/1078-0432.CCR-11-2381
P407
P577
2012-01-19T00:00:00Z